Agenus Inc. (AGEN) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology, primarily advancing its lead program, botensilimab (BOT) in combination with balstilimab (BAL). The quarter was defined by a strategic realignment, including the sale of manufacturing assets to Zydus Lifesciences Ltd., the commencement of the global Phase 3 BATTMAN trial, and the resolution of an SEC investigation.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $33.7 million | $24.1 million |
| Net Income (Loss) | $39.2 million | ($26.4 million) |
| Operating Income (Loss) | $15.1 million | ($13.3 million) |
| R&D Expenses | $11.8 million | $21.5 million |
| G&A Expenses | $6.9 million | $15.7 million |
| Cash and Cash Equivalents | $35.0 million | $18.5 million |
| Total Debt (Principal) | $30.5 million | $45.5 million |
| Accumulated Deficit | ($2.14 billion) | ($2.21 billion) |
Note: Revenue includes $29.1 million of non-cash royalty revenue related to the sale of future royalties. Net income includes a $40.4 million gain on the Zydus asset sale.
Material Changes vs. Prior Period
- Profitability Turnaround: The Company reported a net income of $39.2 million compared to a net loss of $26.4 million in Q1 2025. This shift is primarily driven by a $40.4 million gain on the sale of manufacturing assets to Zydus and a significant reduction in operating expenses.
- Expense Reduction: Operating expenses decreased by approximately 50% year-over-year. R&D expenses fell 45% and G&A expenses fell 56%, largely due to headcount reductions following the sale of manufacturing operations and the deconsolidation of MiNK Therapeutics.
- Liquidity Improvement: Cash and cash equivalents increased from $3.0 million at year-end 2025 to $35.0 million at March 31, 2026, following the receipt of $91.0 million in consideration from Zydus (net of adjustments) and the repayment of a $5.2 million related-party note by MiNK.
- Debt Reduction: Total debt principal decreased from $45.5 million to $30.5 million, aided by the repayment of the Zydus Promissory Note and 2015 Subordinated Notes.
Guidance, Outlook, and Risks
- Strategic Outlook: Management intends to seek Accelerated Approval in the U.S. and Conditional Approval in the EU for BOT/BAL in refractory microsatellite-stable metastatic colorectal cancer during 2026. The global Phase 3 BATTMAN trial has commenced patient enrollment.
- Liquidity and Going Concern: Despite improved cash balances, the filing states that substantial doubt exists about the Company's ability to continue as a going concern for at least one year after the filing date. Management believes existing resources and anticipated revenues will support operations into 2027, but additional capital will be required to achieve profitability.
- Legal Proceedings: The SEC concluded its investigation in May 2026 with no enforcement action recommended. A putative securities class action was dismissed by the District Court in March 2026, though the plaintiff has filed an appeal.
- Unusual Items: The financial results are significantly impacted by the non-recurring gain on the Zydus asset sale and the recognition of non-cash royalty revenue. Cash payments of $18.0 million were made to CDMOs and CROs to settle prior period liabilities, which reduced cash but did not impact Q1 operating expenses.
Investor Verification Checklist
- Gain Sustainability: Verify the non-recurring nature of the $40.4 million gain on the Zydus asset sale and its impact on the reported net income.
- Cash Burn Rate: Assess the "substantial doubt" going concern warning against the $35.0 million cash balance and the $18.0 million in recent CDMO/CRO payments.
- Debt Maturity: Confirm the repayment schedule for the remaining $30.5 million debt, with $5.1 million due in June 2026 and $24.75 million due in November 2026.
- Regulatory Timeline: Monitor the progress of the Phase 3 BATTMAN trial and the timeline for the planned U.S. Accelerated Approval submission.
- Legal Appeals: Track the status of the appeal filed by the lead plaintiff in the securities class action litigation.